In Vitro Activity of the New Triazole BMS-207147 against Aspergillus Species in Comparison with Itraconazole and Amphotericin B
AUTOR(ES)
Moore, Caroline B.
FONTE
American Society for Microbiology
RESUMO
The in vitro activity of BMS-207147 against 80 clinical isolates of Aspergillus was compared with that of itraconazole and amphotericin B, using a validated microtiter method. Geometric mean MICs (in μg/ml) were as follows: 1.71 for BMS-207147, 0.67 for itraconazole, and 0.63 for amphotericin B. The range of concentrations of each drug was 0.125 to >16 μg/ml. Aspergillus fumigatus was significantly more susceptible to BMS-207147 (P < 0.05) than A. terreus and A. flavus. No BMS-207147-resistant A. fumigatus isolates were identified, though eight itraconazole-resistant (MIC, >8 μg/ml) isolates were. BMS-207147 is active against Aspergillus spp. at slightly high concentrations compared with itraconazole and amphotericin B.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=89701Documentos Relacionados
- In Vitro Activity of a New Oral Triazole, BMS-207147 (ER-30346)
- In Vitro Activity of a New Oral Triazole, BMS-207147 (ER-30346)
- In Vitro Activities of Terbinafine against Aspergillus Species in Comparison with Those of Itraconazole and Amphotericin B
- In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp.
- In Vitro Activity of the Echinocandin Antifungal Agent LY303,366 in Comparison with Itraconazole and Amphotericin B against Aspergillus spp.
